A detailed history of Wellington Management Group LLP transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 1,033,927 shares of TRDA stock, worth $17.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,033,927
Previous 1,026,840 0.69%
Holding current value
$17.8 Million
Previous $14.6 Million 1.26%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$11.85 - $16.45 $83,980 - $116,581
7,087 Added 0.69%
1,033,927 $14.7 Million
Q1 2024

May 15, 2024

BUY
$11.58 - $17.0 $11.9 Million - $17.5 Million
1,026,840 New
1,026,840 $14.6 Million
Q4 2023

Feb 12, 2024

BUY
$11.36 - $16.99 $11.9 Million - $17.8 Million
1,047,780 New
1,047,780 $15.8 Million
Q3 2023

Nov 14, 2023

BUY
$13.61 - $18.01 $355,819 - $470,853
26,144 Added 2.56%
1,045,652 $16.5 Million
Q2 2023

Aug 14, 2023

BUY
$11.02 - $18.01 $55,706 - $91,040
5,055 Added 0.5%
1,019,508 $15.4 Million
Q1 2023

May 12, 2023

BUY
$9.58 - $16.2 $39,297 - $66,452
4,102 Added 0.41%
1,014,453 $14.7 Million
Q4 2022

Feb 13, 2023

BUY
$13.52 - $22.89 $41,979 - $71,073
3,105 Added 0.31%
1,010,351 $13.7 Million
Q3 2022

Nov 14, 2022

SELL
$9.65 - $15.76 $5.1 Million - $8.33 Million
-528,637 Reduced 34.42%
1,007,246 $15.9 Million
Q2 2022

Aug 15, 2022

SELL
$5.49 - $12.94 $5.53 Million - $13 Million
-1,007,219 Reduced 39.61%
1,535,883 $18.7 Million
Q1 2022

May 16, 2022

SELL
$7.99 - $16.93 $4.56 Million - $9.67 Million
-570,904 Reduced 18.33%
2,543,102 $23.8 Million
Q4 2021

Feb 11, 2022

BUY
$13.7 - $35.0 $42.7 Million - $109 Million
3,114,006 New
3,114,006 $52.8 Million

Others Institutions Holding TRDA

About Entrada Therapeutics, Inc.


  • Ticker TRDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,368,500
  • Market Cap $540M
  • Description
  • Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...
More about TRDA
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.